ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on finding, developing, and selling distinct medicines for cancer patients with unmet medical needs. The company uses its team's drug development experience to advance its main product candidate, firmonertinib, and a pipeline of new treatments, including next-generation antibody drug conjugates like ARR-217 (MRG007), through approval and commercialization for cancer patients, initially focusing on solid tumors. Firmonertinib is currently in multiple clinical trials for various epidermal growth factor receptor (EGFR) mutations (EGFRm) in non-small cell lung cancer (NSCLC). ArriVent is conducting a pivotal Phase 3 clinical trial of firmonertinib in treatment-naive, or first-line, patients with locally advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations. It is also conducting another pivotal Phase 3 clinical trial of firmonertinib in first-line patients with locally advanced or metastatic EGFRm NSCLC with P-loop and-alpha-c-helix compressing (PACC) mutations. Additionally, a Phase 1 clinical trial for ARR-217 is underway in patients with unresectable locally advanced or metastatic solid tumors. The U.S. Food and Drug Administration (FDA) granted firmonertinib Breakthrough Therapy Designation (BTD) for first-line EGFRm NSCLC with exon 20 insertion in October 2023. Firmonertinib also received Orphan Drug Designation for treating NSCLC with EGFRm or human epidermal growth factor receptor 2 (HER2) mutations or human epidermal growth factor receptor 4 (HER4) mutations in February 2024.